The Covid-19 pandemic is expected to further affect RhoVac’s clinical phase IIb study
Lund, October 12, 2020. RhoVac AB (“RhoVac”) announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 (“BRaVac”), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitment rate in September now indicates full recruitment in Q2 2021. To reduce the effect of the delays caused by the pandemic, the number of clinics will be increased. The study is still expected to be carried out with existing funding.BRaVac is a randomized, placebo-controlled and double-blind study, with the primary